Navigation Links
Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Date:6/10/2008

Collaboration to Apply Chemetics(R) Technology to Lexicon Targets

COPENHAGEN, June 10 /PRNewswire/ -- Nuevolution A/S today announced a strategic alliance with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) aimed at the discovery of novel small molecule lead compounds for highly validated drug targets.

Under the terms of the alliance, Nuevolution's proprietary Chemetics(R) drug discovery technology will be applied to identify novel small molecule lead compounds against a range of drug targets proposed by Lexicon. Nuevolution will receive an upfront payment and will be eligible for milestone payments and royalties on compounds identified using its technology as candidate molecules progress through preclinical and clinical development and onto the market. At a future point in time, Nuevolution will have the option to expand its involvement in certain programs under a cost and profit sharing arrangement.

The collaboration will harness the power of Nuevolution's Chemetics(R) platform technology which enables both hit identification and hit-to-lead optimization by exploration of ultra large chemistry space through the screening of multiple fragment-based small molecule libraries of more than 100 million compounds per library.

The validated targets have been identified through Lexicon's Genome5000TM program where the company explored the physiological and behavioral function for nearly 5,000 human genes by studying the corresponding mouse genes in knockout animals. This endeavor led to the identification of more than 100 highly validated drug targets that Lexicon is using to build a unique and growing clinical pipeline.

"Our proprietary Chemetics(R) platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale," said Alex Gouliaev, CEO of Nuevolution A/S. "We believe this generates high quality hits and leads far more rapidly and reliably than current ultra high throughput methods. Combining our platform with Lexicon's highly validated target portfolio represents an exceptional drug discovery opportunity and we very much look forward to bringing together Lexicon's expertise in biology and ours in chemistry, creating a synergistic biotech alliance."

"This important alliance is designed to accelerate Lexicon's ability to move from novel knockout validated targets to drug candidates as we continue to build our pipeline of innovative products," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer of Lexicon.

About Nuevolution

Nuevolution is a leading drug discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S.

For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

For further information please contact:

Nuevolution A/S

Danish media International media

Alex Haahr Gouliaev, CEO Chris Gardner/Mark Swallow

Phone: +45-7020-0987 Phone: +44(0)207-282-2995/+44(0)207-282-2948

ahg@nuevolution.com chris.gardner@citigatedr.co.uk

Lexicon Pharmaceuticals, Inc.

Stephen Tragash, Executive Director, Corporate Affairs

Phone: +1-281-863-3787

stragash@lexpharma.com


'/>"/>
SOURCE Nuevolution A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. onTargetjobs Announces Appointment of Michael Tansey as New CEO
2. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
3. QLT announces positive Health Canada decision on Aczone(R)
4. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
5. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
6. Biopure Announces MHRA Meeting Update
7. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
8. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
9. American Oriental Bioengineering Announces that it Withdraws Convertible Preferred Stock Offering
10. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
11. Synthetech Announces Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced ... On Azure, Arvados provides capabilities for managing and processing genomic and health data ... from major institutions collecting and analyzing genomic data,” said Adam Berrey chief executive ...
(Date:2/10/2016)... La Jolla CA (PRWEB) , ... February 10, 2016 , ... ... of new agents for the treatment of Alzheimer’s disease, announced today it has been ... to February 18th at the Breakers in Palm Beach, Florida. The purpose of ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election ... Health Care Business Conference will bring together over 500 top healthcare leaders for a ... in transformation. The conference, organized by MBA students of the University of Pennsylvania’s Wharton ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date ... S. Blumberg Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old ... Commonwealth Medical College (TCMC) will hold an open house for participants to learn ...
Breaking Biology Technology:
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):